Dell Announces Funding For Pediatric Cancer Research



Dell announced a multi-million dollar, multi-year commitment to support pediatric cancer research programs globally, including the world’s first personalized medicine trial for pediatric cancer conducted by the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC). Dell has commited funding and help with cloud technology, as well as employee engagement, as expansion of company’s overall philanthropic program. The company did not say exactly how much it would end up funding.

Since the 1980s, the Food and Drug Administration (FDA) has approved only one new treatment for any type of childhood cancer, compared with 50 approved treatments for adult cancers in the same time period.